The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. (Q38940707)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alessia Bari

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stefano Sacchi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Maria Cosenza

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Monica Civallero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Luigi Marcheselli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

13 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

published in

Hematological Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

166-175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

Rituximab in indolent lymphomas

22 February 2020

cites work

1 reference

Targeted drug delivery for cancer therapy: the other side of antibodies

21 January 2018

1 reference

Non-Hodgkin's lymphoma: the old and the new.

21 January 2018

1 reference

Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside

21 January 2018

1 reference

Update on the proteasome inhibitor bortezomib in hematologic malignancies

21 January 2018

1 reference

Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

21 January 2018

1 reference

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

Development of the proteasome inhibitor Velcade (Bortezomib).

21 January 2018

1 reference

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 January 2018

1 reference

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

21 January 2018

1 reference

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

21 January 2018

1 reference

Genomic profiling of enzastaurin-treated B cell lymphoma RL cells.

21 January 2018

1 reference

Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

21 January 2018

1 reference

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

21 January 2018

1 reference

Lenalidomide for the treatment of B-cell malignancies

21 January 2018

1 reference

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

New targets for lymphoma treatment

21 January 2018

1 reference

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

21 January 2018

1 reference

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway

21 January 2018

1 reference

In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines

21 January 2018

1 reference

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

21 January 2018

1 reference

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

21 January 2018

1 reference

Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway

21 January 2018

1 reference

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

21 January 2018

1 reference

Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes

21 January 2018

1 reference

The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma

21 January 2018

1 reference

Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context

21 January 2018

1 reference

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Lenalidomide in the treatment of chronic lymphocytic leukemia

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Oncogenomics to target myeloma in the bone marrow microenvironment

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HON.2179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25394177%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference